BRAF and cancer: Both Grover- and Darier-like eruptions have been reported as common cutaneous toxicities of systemic therapy with B-RAF inhibitors, including dabrafenib and vemurafenib (15, 16), which are utilized in the treatment of BRAF mutant cancers such as melanoma (17–20).